EE34 Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Meropenem for the Treatment of Serious Infections Due to Gram-Negative Bacteria for Which There Are Limited Treatment Options (LTO) in Italy
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.307
https://www.valueinhealthjournal.com/article/S1098-3015(23)03437-X/fulltext
Title :
EE34 Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Meropenem for the Treatment of Serious Infections Due to Gram-Negative Bacteria for Which There Are Limited Treatment Options (LTO) in Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03437-X&doi=10.1016/j.jval.2023.09.307
First page :
Section Title :
Open access? :
No
Section Order :
12328